Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL.

Thangavadivel S, Byrd JC
Cancer Discov 9 320-322 03/01/2019


In this issue, Blombery and colleagues show that the chronic lymphocytic leukemia (CLL) cells bearing Gly101Val mutation confer resistance to venetoclax by reducing the affinity of BCL2 for venetoclax by 180-fold in cell lines and in patient cells. Detection of this mutation provides a potential biomarker for impending disease progression and an opportunity for targeted and combinational therapy to treat CLL.

Full Text